コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 thritis is a common, complex disease with no curative therapy.
2 ctory prostate cancer, for which there is no curative therapy.
3 , and currently remains the only potentially curative therapy.
4 gressive primary brain tumor with no current curative therapy.
5 only those men with significant cancers for curative therapy.
6 atedly interpreted as providing evidence for curative therapy.
7 lar pancreatic cancer, which lacks effective curative therapy.
8 ith stem cell transplantation being the only curative therapy.
9 ith stem cell transplantation being the only curative therapy.
10 plantation is currently the only potentially curative therapy.
11 isease with high public health burden and no curative therapy.
12 in the abdomen, a characteristic that limits curative therapy.
13 an 85% of adults worldwide with no permanent curative therapy.
14 istant urothelial carcinoma has no uniformly curative therapy.
15 epresents a significant clinical obstacle to curative therapy.
16 Bone marrow transplantation is the only curative therapy.
17 applies to patients with MT-GCT treated with curative therapy.
18 nfected cells that persist after potentially curative therapy.
19 cell transplantation might be a potentially curative therapy.
20 e showing significant promise as potentially curative therapy.
21 r really have an opportunity for a potential curative therapy.
22 ents remains poor with short survival and no curative therapy.
23 the epileptogenic focus represents the only curative therapy.
24 ancer is notorious for recurrence even after curative therapy.
25 ading to limited availability of options for curative therapies.
26 taking decisions on efficient preventive and curative therapies.
27 tion of this cell population is required for curative therapies.
28 of virus cell entry and open new avenues for curative therapies.
29 /E7 vaccines already in clinical trials into curative therapies.
30 has produced limited clinical benefit and no curative therapies.
31 e and palliative care, and limited access to curative therapies.
32 th bladder cancer do not receive potentially curative therapies.
33 of retinal degeneration that currently lack curative therapies.
34 cer (NSCLC) being considered for potentially curative therapies.
35 ellular carcinoma (HCC) patients who receive curative therapies.
36 o address the unmet need for preventative or curative therapies.
37 problem in the United States; yet, the only curative therapy, a bone marrow transplant (BMT), is sel
38 ng ovarian cancer represent complications of curative therapies and/or underlying susceptibility stat
39 recurrent cervical carcinoma not amenable to curative therapy and at least one prior regimen in the m
41 as not required for immunologically specific curative therapy and induction of memory provided that a
43 ederal regulations require patients to forgo curative therapies, and they interpret phase I agents as
44 e on early stage tumor detection, receipt of curative therapy, and overall survival in patients with
45 vements in early tumor detection, receipt of curative therapy, and overall survival in patients with
49 is is important because effective, and often curative, therapies are available for many subtypes.
52 ers are not yet treatable and/or are without curative therapies because of our limited understanding
53 transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complic
54 riven proliferation of T-effector cells, but curative therapy can be achieved in nonconditioned hosts
58 f 11 patients (28%) who received potentially curative therapy died, compared with 62 of 71 patients (
59 stance within persisting tumor cells renders curative therapies elusive for the majority of women wit
60 myeloma is a B-cell malignancy for which no curative therapies exist to date, despite enormous resea
62 mains a challenge to clinical medicine, with curative therapy experienced by a minority of patients.
63 ugh international clinical trials, effective curative therapies for about half of patients with sever
64 urpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in
68 resent a path forward for the development of curative therapies for the majority of cancer patients.
72 ic BM transplantation, and thereby provide a curative therapy for a wide spectrum of human diseases.
74 ensive research, but so far no preventive or curative therapy for AD is available, and clinical trial
75 mpared in patients who underwent potentially curative therapy for adenocarcinoma of the pancreatic he
81 ell transplantation (HCT) may offer the only curative therapy for certain life-threatening immune def
82 liver transplantation is currently the only curative therapy for chronic end-stage liver disease and
83 one marrow transplantation (BMT) is the only curative therapy for chronic myelogenous leukemia (CML),
85 c blood or marrow transplantation (BMT) is a curative therapy for chronic myeloid leukemia (CML).
87 Despite intensive efforts in recent years, a curative therapy for cutaneous T-cell lymphoma (CTCL) ha
89 urvival outcomes between patients undergoing curative therapy for HCC in the background of NASH compa
90 y has become an integral part of potentially curative therapy for head and neck cancer and has been i
92 Reduced intensity has allowed a potentially curative therapy for hematologic malignancies to be offe
94 blood and marrow transplantation (BMT) as a curative therapy for hematological malignancies lies in
95 bone marrow transplantation (allo-BMT) is a curative therapy for hematological malignancies, but is
98 diofrequency ablation (RFA) is a potentially curative therapy for hepatocellular carcinoma (HCC).
102 es to evolve as an effective and potentially curative therapy for limited numbers of patients with re
103 tic stem cell transplantation is a potential curative therapy for malignant and nonmalignant diseases
104 c stem cell transplantation is a potentially curative therapy for many malignant and non-malignant he
105 ntation of cord blood provides a potentially curative therapy for many patients without a suitably hu
111 stem cell transplantation (HCT) is the only curative therapy for myelodysplastic syndrome (MDS).
113 ellular immunotherapy (ACT) is a potentially curative therapy for patients with advanced cancer.
114 etic stem cell transplantation (HSCT) offers curative therapy for patients with hemoglobinopathies, c
115 ron-sparing surgery (NSS) provides effective curative therapy for patients with localized renal cell
116 etic cell transplantation offers potentially curative therapy for patients with myelodysplastic syndr
118 lthough surgery remains the only potentially curative therapy for patients with primary GEP-NETs, oth
121 opoietic stem cell transplantation, the only curative therapy for SCD and Thal, is limited by the abs
122 c cell transplantation is, to date, the only curative therapy for SCD, but its application is limited
123 ransplantation (alloHCT) represents the only curative therapy for several hematologic malignancies, a
128 nib and, to date, there remains no effective curative therapy for systemic mastocytosis associated wi
129 ic cell transplantation provides potentially curative therapy for t-MDS, but additional improvements
130 se (NCDB), we examined patients who received curative therapy for the following sites: oral tongue, o
131 marrow transplantation is currently the only curative therapy for the hematopoietic complications of
132 murafenib response with the ultimate goal of curative therapy for the subset of melanoma patients wit
133 arrow transplantation remains the only known curative therapy for these patients and the use of reduc
134 e therapy does appear feasible and may offer curative therapy for those with refractory and relapsed
139 transplantation (BMT) is currently the only curative therapy; however, toxic myeloablative precondit
140 ntial to vastly increase the availability of curative therapy in CLL while retaining a low treatment-
141 reatment paradigms, and deintensification of curative therapy is a current research focus for these p
149 n early stage are candidates for potentially curative therapies (local ablation, resection, or transp
150 tients, but the efficacy of this potentially curative therapy may be limited by poor persistence of T
151 ifferences in recurrence-free survival after curative therapy (median, 60 versus 56 months; P = 0.303
152 r stem cells is believed to be essential for curative therapy of cancers, but supporting evidence is
154 alkylating agents have a central role in the curative therapy of many human tumors; yet, resistance t
155 c stem cell transplantation remains the only curative therapy of MF, but due to its associated morbid
157 ital anemias for which there is presently no curative therapy other than allogeneic hematopoietic ste
160 in order to design safer and more effective curative therapy, particularly for children with SCID di
162 e (41.2% vs. 30.9%), or received potentially curative therapy (resection, transplantation), compared
165 vior, treatment coverage, and the effects of curative therapies that also block Plasmodium parasite t
166 ions with potential to reduce anti-Wolbachia curative therapy times to between one and two weeks.
170 mediate or high grade, for which no standard curative therapy was available, an Eastern Cooperative O
171 osis and offering these patients potentially curative therapy wherever appropriate is of utmost impor
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。